RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
嵌合抗原受体工程化自然杀伤（CAR-NK）细胞治疗急性髓系白血病：文献系统综述
英文原题：Chimeric Antigen Receptor-Engineered Natural Killer (CAR-NK) Cell Therapy in Acute Myeloid Leukemia: A Systematic Review of the Literature.
查看英文原题
Chimeric Antigen Receptor-Engineered Natural Killer (CAR-NK) Cell Therapy in Acute Myeloid Leukemia: A Systematic Review of the Literature.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
工程化嵌合抗原受体自然杀伤（CAR-NK）细胞作为急性髓系白血病（AML）的潜在治疗选择，正受到广泛关注，这源于人们对安全、可规模化生产且有效替代疗法的需求。为概述该领域现状，研究者开展系统综述，评估CAR-NK细胞治疗AML的安全性和疗效。综述结果提示了未来发展的可能方向，同时指出在临床应用前必须解决的重要障碍。因此，尽管CAR-NK疗法仍处于早期阶段，只要这些障碍得到克服，其最终用于AML治疗仍有可能。
展开英文摘要原文
Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells are attracting considerable interest as a potential therapeutic option in acute myeloid leukemia (AML), driven by the search for safe, scalable, and effective alternatives.
To provide an overview of the current state of the field, a systematic review was performed to evaluate the safety and efficacy of CAR-NK cells for AML. The findings suggest possible directions for future development and also highlight important obstacles that must be addressed before they can be used in clinical settings.
Therefore, although CAR-NK therapy remains in its early stages, its eventual application in AML is possible if these barriers can be resolved.
论文信息
- 作者
- Novoa Arias MS
- 单位
- General Medicine, Virrey Solis, Bogota, COL.
- 文献类型
- 综述
- 期刊
- Cureus2025 Oct
- 原文标识
- PubMed 41127493 · DOI 10.7759/cureus.94807
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →